α1-抗胰蛋白酶缺乏症（α1-抗胰蛋白酶缺乏症）肺病市場：依疾病類型、治療方法、給藥途徑、通路及地區分類

預計到 2026 年，α-1 型肺病市場規模將達到 84 億美元，到 2033 年將達到 285.4 億美元。預計從 2026 年到 2033 年，該市場將以 19.1% 的複合年成長率成長。

α1-抗胰蛋白酶缺乏症是一種罕見的遺傳性疾病，會影響肺部和肝臟。它是由α1-抗胰蛋白酶（AAT）缺乏引起的，AAT是一種在保護肺部免受損傷方面發揮作用的蛋白質。這種疾病可導致慢性阻塞性肺病（COPD）和肝病的發生。

全球α1-抗胰蛋白酶缺乏症（α1-抗胰蛋白酶缺乏症）市場成長的促進因素包括該疾病盛行率的上升、醫療專業人員對該疾病認知的提高以及診斷技術的進步。根據α1-抗胰蛋白酶缺乏症基金會估計，美國和歐洲約有10萬人被診斷出患有α1-抗胰蛋白酶缺乏症。然而，實際患者人數可能遠高於此。

市場動態：

α1-抗胰蛋白酶缺乏症（α1-抗胰蛋白酶缺乏症）肺病市場的主要驅動力是該疾病盛行率的上升。隨著越來越多的患者被診斷出患有α1-抗胰蛋白酶缺乏症肺病，對有效治療方法的需求也日益成長。這促使市場上的主要參與者加大了研發投入。

然而，多種因素正在阻礙市場成長。公眾和醫療專業人員對該疾病的認知不足，阻礙了早期診斷和治療。此外，高昂的治療費用以及部分地區缺乏健保覆蓋也對市場成長構成挑戰。

儘管面臨這些挑戰，該市場仍蘊藏著許多成長機會。診斷技術的進步，例如基因檢測，有望提高早期檢出率。此外，新型療法和標靶治療的研發也為治療α-1型肺部疾病帶來了可喜的前景。

例如，2022年6月，美國食品藥物管理局（FDA）的藥物評估與研究中心（CDER）和生技藥品評估與研究中心（CBER）宣布與非營利組織關鍵路徑食品藥物管理局（C-Path）建立合作關係。此舉旨在啟動一個聯盟項目，開發適用於α-1抗胰蛋白酶缺乏症（AATD）臨床開發項目的工具。 AATD是一種罕見疾病，會導致肺組織進行性破壞，最終導致過早死亡和肺移植。

本研究的主要特點：

• 本報告對全球α-1肺病市場進行了詳細分析，包括2026年至2033年預測期內的市場規模和複合年成長率%。
• 此外，它還指出了各個細分市場的潛在成長機會，並說明了該市場具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究涵蓋的主要公司包括Astra Zeneca、勃林格殷格翰國際有限公司、羅氏、諾華、輝瑞、默克、百時美施貴寶、武田藥品工業株式會社、CSL Behring、Vertex Pharmaceuticals, Inc.、安進、賽諾菲、葛蘭素史克、吉利德科學、艾伯維和元再生製藥。
• 本報告提供的見解將有助於行銷負責人和經營團隊就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 這份關於全球α-1肺病市場的報告旨在為該行業的各種相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過利用全球α-1肺病市場分析中所使用的各種策略矩陣來簡化決策過程。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• 連貫機會圖（COaM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
    • 全球慢性阻塞性肺病盛行率正在上升。
    • 診斷率的提高
    • 新產品發布
    • 強大的藥物研發管線
  • 抑制因子
    • 大眾對這種疾病的認知有限。
  • 機會
    • 診斷技術的進步
• 影響分析
• 主要亮點
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特五力分析
• 併購情景

第4章：α1-抗胰蛋白酶缺乏症

• 供給面和需求面分析
• 經濟影響

第5章 α1-抗胰蛋白酶缺乏症肺部疾病市場：依疾病類型分類，2021-2033年

• α-1抗胰蛋白酶缺乏症
• 慢性阻塞性肺病（COPD）
• 肺纖維化
• 支氣管擴張
• 其他

第6章 α1-抗胰蛋白酶缺乏症肺部疾病市場：依治療類型分類，2021-2033年

• 輔助性治療
• 支氣管擴張劑
• 皮質類固醇
• 氧氣療法
• 肺移植
• 其他

第7章 α1-抗胰蛋白酶缺乏症肺部疾病市場：依給藥途徑分類，2021-2033年

• 注射藥物
• 口服
• 其他

第8章 α1-抗胰蛋白酶缺乏症肺部疾病市場：依分銷管道分類，2021-2033年

• 醫院藥房
• 零售藥房
• 網路藥房

第9章 α1-抗胰蛋白酶缺乏症（α1-抗胰蛋白酶缺乏症）肺部疾病市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第10章 競爭格局

• AstraZeneca
• Boehringer Ingelheim International GmbH
• Hoffmann-La Roche Ltd
• Novartis AG
• Pfizer Inc.
• Merck & Co., Inc.
• Bristol-Myers Squibb
• Takeda Pharmaceutical Company Limited.
• CSL Behring
• Vertex Pharmaceuticals Incorporated
• Amgen Inc.
• Sanofi
• GSK plc
• Gilead Sciences, Inc.
• AbbVie Inc.
• Regeneron Pharmaceuticals Inc.

第11章

• 調查方法
• 關於本公司

Alpha 1 Lung Disease Market is estimated to be valued at USD 8.40 Bn in 2026 and is expected to reach USD 28.54 Bn by 2033, growing at a compound annual growth rate (CAGR) of 19.1% from 2026 to 2033.

Alpha 1 Lung Disease is a rare genetic disorder that affects the lungs and liver. It is caused by a deficiency of alpha-1 antitrypsin (AAT), a protein that helps protect the lungs from damage. This condition leads to the development of chronic obstructive pulmonary disease (COPD) and liver disease.

The global Alpha 1 Lung Disease market is driven by the increasing prevalence of the disease, growing awareness among healthcare professionals, and advancements in diagnostic techniques. According to the Alpha-1 Foundation, it is estimated that around 100,000 individuals in the U.S. and Europe have been diagnosed with Alpha 1 Lung Disease. However, the actual number of affected individuals is believed to be much higher.

Market Dynamics:

The market for Alpha 1 Lung Disease is primarily driven by the rising prevalence of the disease. As more individuals are being diagnosed with Alpha 1 Lung Disease, the demand for effective treatment options is increasing. This has led to a surge in research and development activities by key players in the market.

However, there are certain factors that restrain the growth of the market. Limited awareness about the disease among the general population and healthcare professionals hinders early diagnosis and treatment. Additionally, the high cost of treatment and lack of reimbursement policies in some regions pose challenges to market growth.

Despite these challenges, the market presents several opportunities for growth. Technological advancements in diagnostic techniques, such as genetic testing, are expected to improve early detection rates. Moreover, the development of novel therapies and targeted drugs holds promise for the treatment of Alpha 1 Lung Disease.

For instance, in June 2022, U.S. Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), the Center within the U.S. Food and Drug Administration (FDA) are pleased to announce their partnership with the Critical Path Institute (C-Path), a non-profit organization to initiate planning for a consortium aimed at developing tools appropriate for use in clinical development programs for alpha-1 antitrypsin deficiency (AATD), a rare disease causing progressive destruction of lung tissue leading to premature mortality or need for lung transplant.

Key Features of the Study:

• This report provides an in-depth analysis of the global Alpha 1 Lung Disease market, including market size (US$ Bn) and Compound Annual Growth Rate (CAGR %) for the forecast period 2026-2033
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• The key companies covered as a part of this study include AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Merck & Co., Inc., Bristol-Myers Squibb, Takeda Pharmaceutical Company Limited., CSL Behring, Vertex Pharmaceuticals Incorporated, Amgen Inc., Sanofi, GSK plc, Gilead Sciences, Inc., AbbVie Inc., and Regeneron Pharmaceuticals Inc.
• Insights from this report would allow marketers and management authorities to make informed decisions regarding future product launches, type upgrades, market expansion, and marketing tactics
• The global Alpha 1 Lung Disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Alpha 1 Lung Disease market

Alpha 1 Lung Disease Market Segmentation:

• By Disease Type
• Alpha-1 Antitrypsin Deficiency
• Chronic Obstructive Pulmonary Disease (COPD)
• Pulmonary Fibrosis
• Bronchiectasis
• Others
• By Treatment Type
• Augmentation Therapy
• Bronchodilators
• Corticosteroids
• Oxygen Therapy
• Lung Transplantation
• Others
• By Route of Administration
• Injectable
• Oral
• Others
• By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Top Companies in the Alpha 1 Lung Disease Market
• AstraZeneca
• Boehringer Ingelheim International GmbH
• F.Hoffmann-La Roche Ltd
• Novartis AG
• Pfizer Inc.
• Merck & Co., Inc.,
• Bristol-Myers Squibb
• Takeda Pharmaceutical Company Limited.
• CSL Behring
• Vertex Pharmaceuticals Incorporated
• Amgen Inc.
• Sanofi
• GSK plc
• Gilead Sciences, Inc.
• AbbVie Inc.
• Regeneron Pharmaceuticals Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Alpha 1 Lung Disease, By Disease Type
  • Market Alpha 1 Lung Disease, By Treatment Type
  • Market Alpha 1 Lung Disease, By Route of Administration
  • Market Alpha 1 Lung Disease, By Distribution Channel
  • Market Alpha 1 Lung Disease, By Region
• Coherent Opportunity Map (COaM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
    • Rising Prevalence of COPD Globally
    • Increasing Diagnosis Rates
    • New Product Launches
    • Strong Pipeline of Drugs
  • Restraints
    • Limited awareness about the disease among the general population
  • Opportunities
    • Technological advancements in diagnostic techniques
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER€(TM)s Analysis
• Merger and Acquisition Scenario

4. Alpha 1 Lung Disease

• Supply Side and Demand Side Analysis
• Economic Impact

5. Alpha 1 Lung Disease Market, By Disease Type, 2021 - 2033, (US$ Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Alpha-1 Antitrypsin Deficiency
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
• Chronic Obstructive Pulmonary Disease (COPD)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
• Pulmonary Fibrosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
• Bronchiectasis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)

6. Alpha 1 Lung Disease Market, By Treatment Type, 2021 - 2033, (US$ Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Augmentation Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
• Bronchodilators
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
• Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
• Oxygen Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
• Lung Transplantation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)

7. Alpha 1 Lung Disease Market, By Route of Administration, 2021 - 2033, (US$ Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)

8. Alpha 1 Lung Disease Market, By Distribution Channel, 2021 - 2033, (US$ Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Billion)

9. Alpha 1 Lung Disease Market, By Region, 2021 - 2033, (US$ Bn)

• Introduction
  • Market Share Analysis, By Country, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country 2022-2033
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033,(US$ Bn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Boehringer Ingelheim International GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Hoffmann-La Roche Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company Limited.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• CSL Behring
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Vertex Pharmaceuticals Incorporated
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• GSK plc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Gilead Sciences, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• AbbVie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Regeneron Pharmaceuticals Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

11. Section

• Research Methodology
• About us